Effect of L-leucine therapy on hematopoietic function in elderly myelodysplastic syndrome patients

Kaori Ito, Takahiro Hayashi, Yoko Inaguma, Tomohiko Terazawa, Maiko Ando, Yosuke Ando, Masahiro Tsuge, Azusa Kato, Akane Shimato, Shinji Suzuki, Sayaka Kato, Akihiro Tomita, Shigeki Yamada, Nobuhiko Emi

研究成果: Article

抄録

Patients with myelodysplastic syndrome (MDS) often require blood transfusion and anticancer therapy; however, elderly patients are intolerant to the associated side effects of anticancer therapy. Because L-leucine can be used to treat Diamond–Blackfan anemia, which is caused by defects in ribosomal protein (RP) genes, resulting in increased in vivo hemoglobin synthesis, it is possible that some MDS patients who have aberrations in their RP genes could also be effectively treated with L-leucine. In the present study, we investigated the effects of L-leucine on hematopoietic function (reticulocyte count), red blood cell count, and hemoglobin level in MDS patients. We administered L-leucine (1.8g, twice daily, 3d/week) with oral vitamin B6 supplements to a final cohort of eight MDS patients for 15 (interquartile range: 11–18) weeks. We assessed the patients at 10±2 weeks after therapy initiation. Only the absolute reticulocyte count was affected, improving in 6/8 (75%) patients. The median absolute reticulocyte count was 3.5×104 (range: 2.7–6.4×104) cells/µL, an increase of 0.5×104 (range: 0.2–0.7×104) cells/µL. At 10 weeks, there was only one case of an improved hemoglobin level. Non-hematological adverse events of grade 3 were observed one raised triglycerides. These data suggest that L-leucine has little effect on MDS. However, it may contribute to the recovery of hematopoietic function, futher study be desired.

元の言語English
ページ(範囲)1651-1657
ページ数7
ジャーナルBiological and Pharmaceutical Bulletin
42
発行部数10
DOI
出版物ステータスPublished - 01-01-2019

Fingerprint

Myelodysplastic Syndromes
Leucine
Reticulocyte Count
Hemoglobins
Ribosomal Proteins
Therapeutics
Erythrocyte Count
Vitamin B 6
Recovery of Function
Blood Transfusion
Genes
Anemia
Triglycerides

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science

これを引用

Ito, Kaori ; Hayashi, Takahiro ; Inaguma, Yoko ; Terazawa, Tomohiko ; Ando, Maiko ; Ando, Yosuke ; Tsuge, Masahiro ; Kato, Azusa ; Shimato, Akane ; Suzuki, Shinji ; Kato, Sayaka ; Tomita, Akihiro ; Yamada, Shigeki ; Emi, Nobuhiko. / Effect of L-leucine therapy on hematopoietic function in elderly myelodysplastic syndrome patients. :: Biological and Pharmaceutical Bulletin. 2019 ; 巻 42, 番号 10. pp. 1651-1657.
@article{e1aee3dabce04cc39c1ffc0684934c98,
title = "Effect of L-leucine therapy on hematopoietic function in elderly myelodysplastic syndrome patients",
abstract = "Patients with myelodysplastic syndrome (MDS) often require blood transfusion and anticancer therapy; however, elderly patients are intolerant to the associated side effects of anticancer therapy. Because L-leucine can be used to treat Diamond–Blackfan anemia, which is caused by defects in ribosomal protein (RP) genes, resulting in increased in vivo hemoglobin synthesis, it is possible that some MDS patients who have aberrations in their RP genes could also be effectively treated with L-leucine. In the present study, we investigated the effects of L-leucine on hematopoietic function (reticulocyte count), red blood cell count, and hemoglobin level in MDS patients. We administered L-leucine (1.8g, twice daily, 3d/week) with oral vitamin B6 supplements to a final cohort of eight MDS patients for 15 (interquartile range: 11–18) weeks. We assessed the patients at 10±2 weeks after therapy initiation. Only the absolute reticulocyte count was affected, improving in 6/8 (75{\%}) patients. The median absolute reticulocyte count was 3.5×104 (range: 2.7–6.4×104) cells/µL, an increase of 0.5×104 (range: 0.2–0.7×104) cells/µL. At 10 weeks, there was only one case of an improved hemoglobin level. Non-hematological adverse events of grade 3 were observed one raised triglycerides. These data suggest that L-leucine has little effect on MDS. However, it may contribute to the recovery of hematopoietic function, futher study be desired.",
author = "Kaori Ito and Takahiro Hayashi and Yoko Inaguma and Tomohiko Terazawa and Maiko Ando and Yosuke Ando and Masahiro Tsuge and Azusa Kato and Akane Shimato and Shinji Suzuki and Sayaka Kato and Akihiro Tomita and Shigeki Yamada and Nobuhiko Emi",
year = "2019",
month = "1",
day = "1",
doi = "10.1248/bpb.b19-00184",
language = "English",
volume = "42",
pages = "1651--1657",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "10",

}

Ito, K, Hayashi, T, Inaguma, Y, Terazawa, T, Ando, M, Ando, Y, Tsuge, M, Kato, A, Shimato, A, Suzuki, S, Kato, S, Tomita, A, Yamada, S & Emi, N 2019, 'Effect of L-leucine therapy on hematopoietic function in elderly myelodysplastic syndrome patients', Biological and Pharmaceutical Bulletin, 巻. 42, 番号 10, pp. 1651-1657. https://doi.org/10.1248/bpb.b19-00184

Effect of L-leucine therapy on hematopoietic function in elderly myelodysplastic syndrome patients. / Ito, Kaori; Hayashi, Takahiro; Inaguma, Yoko; Terazawa, Tomohiko; Ando, Maiko; Ando, Yosuke; Tsuge, Masahiro; Kato, Azusa; Shimato, Akane; Suzuki, Shinji; Kato, Sayaka; Tomita, Akihiro; Yamada, Shigeki; Emi, Nobuhiko.

:: Biological and Pharmaceutical Bulletin, 巻 42, 番号 10, 01.01.2019, p. 1651-1657.

研究成果: Article

TY - JOUR

T1 - Effect of L-leucine therapy on hematopoietic function in elderly myelodysplastic syndrome patients

AU - Ito, Kaori

AU - Hayashi, Takahiro

AU - Inaguma, Yoko

AU - Terazawa, Tomohiko

AU - Ando, Maiko

AU - Ando, Yosuke

AU - Tsuge, Masahiro

AU - Kato, Azusa

AU - Shimato, Akane

AU - Suzuki, Shinji

AU - Kato, Sayaka

AU - Tomita, Akihiro

AU - Yamada, Shigeki

AU - Emi, Nobuhiko

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Patients with myelodysplastic syndrome (MDS) often require blood transfusion and anticancer therapy; however, elderly patients are intolerant to the associated side effects of anticancer therapy. Because L-leucine can be used to treat Diamond–Blackfan anemia, which is caused by defects in ribosomal protein (RP) genes, resulting in increased in vivo hemoglobin synthesis, it is possible that some MDS patients who have aberrations in their RP genes could also be effectively treated with L-leucine. In the present study, we investigated the effects of L-leucine on hematopoietic function (reticulocyte count), red blood cell count, and hemoglobin level in MDS patients. We administered L-leucine (1.8g, twice daily, 3d/week) with oral vitamin B6 supplements to a final cohort of eight MDS patients for 15 (interquartile range: 11–18) weeks. We assessed the patients at 10±2 weeks after therapy initiation. Only the absolute reticulocyte count was affected, improving in 6/8 (75%) patients. The median absolute reticulocyte count was 3.5×104 (range: 2.7–6.4×104) cells/µL, an increase of 0.5×104 (range: 0.2–0.7×104) cells/µL. At 10 weeks, there was only one case of an improved hemoglobin level. Non-hematological adverse events of grade 3 were observed one raised triglycerides. These data suggest that L-leucine has little effect on MDS. However, it may contribute to the recovery of hematopoietic function, futher study be desired.

AB - Patients with myelodysplastic syndrome (MDS) often require blood transfusion and anticancer therapy; however, elderly patients are intolerant to the associated side effects of anticancer therapy. Because L-leucine can be used to treat Diamond–Blackfan anemia, which is caused by defects in ribosomal protein (RP) genes, resulting in increased in vivo hemoglobin synthesis, it is possible that some MDS patients who have aberrations in their RP genes could also be effectively treated with L-leucine. In the present study, we investigated the effects of L-leucine on hematopoietic function (reticulocyte count), red blood cell count, and hemoglobin level in MDS patients. We administered L-leucine (1.8g, twice daily, 3d/week) with oral vitamin B6 supplements to a final cohort of eight MDS patients for 15 (interquartile range: 11–18) weeks. We assessed the patients at 10±2 weeks after therapy initiation. Only the absolute reticulocyte count was affected, improving in 6/8 (75%) patients. The median absolute reticulocyte count was 3.5×104 (range: 2.7–6.4×104) cells/µL, an increase of 0.5×104 (range: 0.2–0.7×104) cells/µL. At 10 weeks, there was only one case of an improved hemoglobin level. Non-hematological adverse events of grade 3 were observed one raised triglycerides. These data suggest that L-leucine has little effect on MDS. However, it may contribute to the recovery of hematopoietic function, futher study be desired.

UR - http://www.scopus.com/inward/record.url?scp=85072784223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072784223&partnerID=8YFLogxK

U2 - 10.1248/bpb.b19-00184

DO - 10.1248/bpb.b19-00184

M3 - Article

C2 - 31341143

AN - SCOPUS:85072784223

VL - 42

SP - 1651

EP - 1657

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 10

ER -